Fuller & Thaler Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Fuller & Thaler Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302K	Sell	49,360 -390	-0.8%	-$2.55K	﹤0.01%	492
2026 Q1	$344K	Hold	49,750	–	–	﹤0.01%	463
2025 Q4	$439K	Hold	49,750	–	–	﹤0.01%	453
2025 Q3	$248K	Hold	49,750	–	–	﹤0.01%	488
2025 Q2	$235K	Sell	49,750 -11,170	-18%	-$48.8K	﹤0.01%	491
2025 Q1	$280K	Buy	60,920 +800	+1%	+$3.73K	﹤0.01%	492
2024 Q4	$288K	Hold	60,120	–	–	﹤0.01%	501
2024 Q3	$282K	Buy	+60,120	New	+$322K	﹤0.01%	490

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fuller & Thaler Asset Management's VNDA Position: Q2 2026 in Review

Fuller & Thaler Asset Management reduced its Vanda Pharmaceuticals (VNDA) stake by 0.78% in Q2 2026, selling an estimated $2.55K and leaving 49,360 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #492.

Fuller & Thaler Asset Management first reported a position in VNDA in Q3 2024 and has held it in 8 quarters since. The position peaked at $439K in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Fuller & Thaler Asset Management held 49,360 shares of Vanda Pharmaceuticals worth $302K as of Q2 2026.
Fuller & Thaler Asset Management sold 390 Vanda Pharmaceuticals shares in Q2 2026, an estimated $2.55K.
Vanda Pharmaceuticals made up ﹤0.01% of Fuller & Thaler Asset Management's portfolio in Q2 2026, its #492 holding.
Fuller & Thaler Asset Management first reported a position in Vanda Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Fuller & Thaler Asset Management's Vanda Pharmaceuticals position peaked at $439K in Q4 2025.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.